Sanofi has completed its acquisition of Dynavax Technologies Corporation for $15.50 per share in cash. The deal includes Dynavax's hepatitis B vaccine HEPLISAV-B, a shingles vaccine candidate in phase 1/2 studies, and additional vaccine pipeline projects. The acquisition strengthens Sanofi's adult immunization portfolio by combining Dynavax's vac...

Sanofi has completed its acquisition of Dynavax Technologies Corporation for $15.50 per share. The deal includes Dynavax's hepatitis B vaccine HEPLISAV-B, a shingles vaccine candidate (Z-1018) in Phase 1/2 trials, and other vaccine development projects. The acquisition strengthens Sanofi's position in adult vaccination with access to Dynavax's co...

David Novack, President & COO of Dynavax Technologies, exercised and sold 114,000 shares for approximately $1.8 million on January 15, 2026, netting about $680,000 after costs. The sale comes following Dynavax's announcement of a $2.2 billion acquisition by French pharmaceutical giant Sanofi at $15.50 per share, representing a 40% premium to Dece...

Class action law firm Monteverde & Associates PC is investigating four merger and acquisition transactions: Dynavax Technologies' sale to Sanofi ($15.50/share), FONAR Corporation's sale to affiliates of its CEO ($19.00-$6.34/share), DigitalBridge Group's sale to SoftBank ($16.00/share), and ON24's sale to Cvent Atlanta ($8.10/share). The firm is ...

Monteverde & Associates PC, a securities class action firm, has announced an investigation into Dynavax Technologies Corporation's proposed acquisition by Sanofi. Under the deal terms, Dynavax shareholders are expected to receive $15.50 per share in cash. The firm is examining whether the transaction represents a fair deal for shareholders.